Meeting
2021 ASCO Annual Meeting
Maintenance immunosuppressive therapy with resumption of immune checkpoint inhibitor treatment to reduce recurrence of immune-mediated colitis.
Authors
Hamzah Abu-Sbeih
University of Missouri, Kansas City, MO
Hamzah Abu-Sbeih , Fangwen Zou , Barbara Dutra , Mehmet Altan , Jennifer Leigh McQuade , John A. Thompson , Anusha Thomas , Yinghong Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2642)
DOI
10.1200/JCO.2021.39.15_suppl.2642
Abstract #
2642
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study.
First Author: Hamzah Abu-Sbeih
Poster
2019 ASCO Annual Meeting
Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy.
First Author: Hamzah Abu-Sbeih
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Role of proton pump inhibitors in immune checkpoint inhibitor colitis.
First Author: Roshini Pradeep
Poster
2023 ASCO Annual Meeting
Tumor mutational burden (TMB) in real-world patients with pancreatic ductal adenocarcinoma (PDAC): Differences in genomic alterations (GA) and predictive value for immune checkpoint inhibitor (ICI) effectiveness.
First Author: Amit Mahipal